Neurosense Therapeutics Ltd(NRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRSN Neurosense Therapeutics Ltd

Closed 03-20 16:00:00 EDT

0.7530

-0.0357

-4.53%

盘后0.7305

-0.0225-2.99%

19:20 EDT

High0.8150	Low0.7500	Vol165.99K
Open0.7800	D1 Closing0.7887	Amplitude8.24%
Mkt Cap25.15M	Tradable Cap16.65M	Total Shares33.40M
T/O128.98K	T/O Rate0.75%	Tradable Shares22.11M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NRSN","market":"US","secType":"STK","nameCN":"Neurosense Therapeutics Ltd","latestPrice":0.753,"timestamp":1774036800000,"preClose":0.7887,"halted":0,"volume":165991,"hourTrading":{"tag":"盘后","latestPrice":0.7305,"preClose":0.753,"latestTime":"19:20 EDT","volume":55089,"amount":42365.3019,"timestamp":1774048824833,"change":-0.0225,"changeRate":-0.02988,"amplitude":0.105578},"delay":0,"changeRate":-0.045264359071890393,"floatShares":22107900,"shares":33396600,"eps":-0.377806,"marketStatus":"Closed","change":-0.0357,"latestTime":"03-20 16:00:00 EDT","open":0.78,"high":0.815,"low":0.75,"amount":128978.30358126,"amplitude":0.082414,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.377806,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":5,"adr":0,"listingDate":1639026000000,"exchange":"NASDAQ","adjPreClose":0.7887,"preHourTrading":{"tag":"盘前","latestPrice":0.8044,"preClose":0.7887,"latestTime":"08:00 EDT","volume":50,"amount":40.22,"timestamp":1774008003130,"change":0.0157,"changeRate":0.019906,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":0.7305,"preClose":0.753,"latestTime":"19:20 EDT","volume":55089,"amount":42365.3019,"timestamp":1774048824833,"change":-0.0225,"changeRate":-0.02988,"amplitude":0.105578},"volumeRatio":0.485023},"requestUrl":"/m/hq/s/NRSN","defaultTab":"news","newsList":[{"id":"2620208261","title":"NeuroSense Therapeutics Director Cary J. Claiborne Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620208261","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620208261?lang=en_us&edition=fundamental","pubTime":"2026-03-19 03:36","pubTimestamp":1773862603,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics director Cary Claiborne filed an initial statement of beneficial ownership. Claiborne reported directly owning 48,000 ordinary shares. He also reported directly owning 60,000 ordinary shares and 99,898 ordinary shares. Claiborne reported options to purchase 72,000 ordinary shares at an exercise price of USD 1.43.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL4mh6sd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2620261222","title":"NeuroSense Therapeutics Ltd. Director Roy Golan Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620261222","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620261222?lang=en_us&edition=fundamental","pubTime":"2026-03-19 03:36","pubTimestamp":1773862587,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics reported an initial statement of beneficial ownership for director Roy Golan. Golan reported direct beneficial ownership of 24,000 ordinary shares. Golan also reported direct beneficial ownership of 60,000 ordinary shares. Golan also reported direct beneficial ownership of 76,844 ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL6Gn9Mg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2620261270","title":"NeuroSense Therapeutics Ltd. Director Mark Leuchtenberger Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620261270","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620261270?lang=en_us&edition=fundamental","pubTime":"2026-03-19 03:36","pubTimestamp":1773862576,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics reported an initial statement of beneficial ownership by director Mark Leuchtenberger. Mark Leuchtenberger reported direct beneficial ownership of 128,000 ordinary shares. He also reported direct beneficial ownership of 75,000 ordinary shares. He also reported direct beneficial ownership of 122,951 ordinary shares. Mark Leuchtenberger reported fully vested options to purchase 192,000 ordinary shares at a conversion or exercise price of USD 4.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL9zB1kW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2620253314","title":"NeuroSense to Present PrimeC Phase 2b PARADIGM Data at AD/PD 2026 Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2620253314","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620253314?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:04","pubTimestamp":1773835472,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire  on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL1fLsDM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"gpt_icon":0},{"id":"2620470649","title":"Health Rounds: Blood test improves detection of endometriosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2620470649","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620470649?lang=en_us&edition=fundamental","pubTime":"2026-03-18 03:31","pubTimestamp":1773775865,"startTime":"0","endTime":"0","summary":"Health Rounds: Blood test improves detection of endometriosis Health Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us?Forward this newsletter to them. They can also subscribe hereBy Nancy LapidMarch 17  - Hello Health Rounds readers!","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nL1N4050X2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","LU1839511570.USD","BK4585","BK4588","NRSN","BK4139","LU2087621335.USD","VTRS","BK4007"],"gpt_icon":0},{"id":"2620405478","title":"Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Assertio Therapeutics (ASRT) and LENSAR (LNSR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620405478","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620405478?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:40","pubTimestamp":1773754806,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Neurosense Therapeutics Ltd. (NRSN – Research Repo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neurosense-therapeutics-ltd-nrsn-assertio-therapeutics-asrt-and-lensar-lnsr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neurosense-therapeutics-ltd-nrsn-assertio-therapeutics-asrt-and-lensar-lnsr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","LABU","BK4082","ASRT","HCSG","LU0029874061.USD","LU0128526141.USD","BK4588","NRSN","BK4581","BK4007","BK4139","XLV","BK4585","LNSR","BK4137"],"gpt_icon":0},{"id":"2619462144","title":"NeuroSense Phase 2b PARADIGM trial links PrimeC to 36% slower ALS progression and 64% lower complication risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2619462144","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619462144?lang=en_us&edition=fundamental","pubTime":"2026-03-16 23:34","pubTimestamp":1773675245,"startTime":"0","endTime":"0","summary":"NeuroSense reported that results from its PARADIGM Phase 2b randomized, double-blind, placebo-controlled trial of PrimeC in amyotrophic lateral sclerosis were published in JAMA Neurology, following a 6-month blinded period and a 12-month open-label extension. Continuous PrimeC treatment was associated with a 7.92-point ALSFRS-R advantage at 18 months versus placebo, and a 64% relative reduction in risk of ALS-related complications with early initiation. The publication also reported modulation of ALS-related microRNAs and iron-regulatory biomarkers, including downregulation of miR-199a-3p and stabilization of ferritin. NeuroSense said the findings supported advancement of PrimeC to a confirmatory Phase 3 trial in ALS, and that the Phase 3 trial has received FDA clearance to proceed.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL94Rthf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"gpt_icon":0},{"id":"2619111462","title":"Jama Neurology Publishes Results From Paradigm Phase 2B Trial of Primec in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity","url":"https://stock-news.laohu8.com/highlight/detail?id=2619111462","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619111462?lang=en_us&edition=fundamental","pubTime":"2026-03-16 23:33","pubTimestamp":1773675222,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA4TXKPT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRSN","NRSNW","BK4139"],"gpt_icon":0},{"id":"2618944271","title":"NeuroSense Therapeutics shareholders approve articles amendment to increase registered share capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2618944271","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618944271?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:02","pubTimestamp":1773230531,"startTime":"0","endTime":"0","summary":"NeuroSense shareholders approved a resolution at a March 10, 2026 special meeting to amend the company’s articles of association to increase its registered share capital.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL9JL6P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2618932751","title":"Roth Capital Partners Initiates Neurosense Therapeutics at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2618932751","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618932751?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:35","pubTimestamp":1773142532,"startTime":"0","endTime":"0","summary":"Roth Capital Partners Initiates Neurosense Therapeutics at Buy","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","NRSN","BK4539","BK4007","LENZ"],"gpt_icon":0},{"id":"2618938379","title":"NeuroSense initiated with a Buy at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2618938379","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618938379?lang=en_us&edition=fundamental","pubTime":"2026-03-10 16:30","pubTimestamp":1773131439,"startTime":"0","endTime":"0","summary":"Roth Capital analyst Boobalan Pachaiyappan initiated coverage of NeuroSense (NRSN) with a Buy rating and $3 price target The firm is positive on Pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurosense-initiated-with-a-buy-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurosense-initiated-with-a-buy-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRSN","BK4139"],"gpt_icon":0},{"id":"2618988022","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neurosense Therapeutics Ltd. (NRSN) and Novo Nordisk (NVO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618988022","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618988022?lang=en_us&edition=fundamental","pubTime":"2026-03-10 12:30","pubTimestamp":1773117012,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neurosense Therapeutics Ltd. (NRSN – Research Report) and Novo No...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-neurosense-therapeutics-ltd-nrsn-and-novo-nordisk-nvo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-neurosense-therapeutics-ltd-nrsn-and-novo-nordisk-nvo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LU0154236417.USD","BK4585","BK4139","BK4581","NVOH","BK4137","BK4532","LU1093756168.USD","BK4588","NVO","LABU","XBI","BK4599","IE00BZ1G4Q59.USD","LU0029874061.USD","NVOX","IE00BKVL7J92.USD","LU1093756325.SGD","LU0128526141.USD","NRSN"],"gpt_icon":0},{"id":"2612449027","title":"NeuroSense reports additional long-term survival data from PARADIGM 2b trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2612449027","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612449027?lang=en_us&edition=fundamental","pubTime":"2026-02-18 22:10","pubTimestamp":1771423854,"startTime":"0","endTime":"0","summary":"NeuroSense (NRSN) Therapeutics announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b cli...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurosense-reports-additional-long-term-survival-data-from-paradigm-2b-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurosense-reports-additional-long-term-survival-data-from-paradigm-2b-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2612449432","title":"NeuroSense reports PrimeC cut ALS death risk 65% in Phase 2b trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2612449432","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612449432?lang=en_us&edition=fundamental","pubTime":"2026-02-18 22:05","pubTimestamp":1771423518,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics Ltd. announced additional long-term overall survival data from its previously completed PARADIGM Phase 2b randomized, double-blind, placebo-controlled trial of PrimeC in amyotrophic lateral sclerosis . In an updated extended follow-up analysis, patients who received PrimeC continuously during the double-blind and open-label phases had an estimated median survival of 36.3 months versus 21.4 months for patients initially assigned to placebo who crossed over to active treatment; the log-rank test reported p=0.0218. A Cox model analysis reported a hazard ratio of 0.35 , corresponding to a 65% reduction in risk of death versus placebo. The results were reported as newly available additional analyses from the completed study, with no future presentation indicated.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL2BwVsy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2611193255","title":"NeuroSense Therapeutics Proposes Increase in Registered Share Capital at Upcoming Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2611193255","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611193255?lang=en_us&edition=fundamental","pubTime":"2026-02-14 05:35","pubTimestamp":1771018557,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics Ltd. will hold a special meeting of shareholders on March 10, 2026, to vote on a proposal to amend the company’s Articles of Association to increase its registered share capital. The Board of Directors recommends voting in favor of the proposal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL7zVVQH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2610562166","title":"NeuroSense erhält australisches Patent für PrimeC-Kombinationstherapie","url":"https://stock-news.laohu8.com/highlight/detail?id=2610562166","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610562166?lang=en_us&edition=fundamental","pubTime":"2026-02-09 22:20","pubTimestamp":1770646818,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics Ltd. hat bekanntgegeben, dass das australische Patentamt ein Patent für die Zusammensetzung von PrimeC erteilt hat. Das Patent schützt die Kombination aus Ciprofloxacin und Celecoxib und gilt bis Oktober 2042.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire  on February 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDLbJXQV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2607052272","title":"NeuroSense files $150M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2607052272","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607052272?lang=en_us&edition=fundamental","pubTime":"2026-01-30 06:30","pubTimestamp":1769725820,"startTime":"0","endTime":"0","summary":"17:29 EST NeuroSense (NRSN) files $150M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breakin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurosense-files-150m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurosense-files-150m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2607705266","title":"Neurosense Therapeutics Ltd : Files for Mixed Shelf Offering of up to $150 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2607705266","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607705266?lang=en_us&edition=fundamental","pubTime":"2026-01-30 06:29","pubTimestamp":1769725754,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nFWN3YU1HX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRSN","BK4139"],"gpt_icon":0},{"id":"2605728107","title":"NeuroSense Therapeutics Granted U.S. Patent for Alzheimer's Disease Treatment, Extending Protection Through 2043","url":"https://stock-news.laohu8.com/highlight/detail?id=2605728107","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605728107?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:31","pubTimestamp":1769002264,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics Ltd. has been granted U.S. Patent No. 12,527,768 for compositions comprising an anti-inflammatory drug and a Dicer activator for use in the treatment of neuronal diseases, specifically Alzheimer's disease. The patent provides protection for the PrimeC combination therapy through 2043. The company's recent proof-of-concept study for Alzheimer's disease demonstrated a favorable safety and tolerability profile, with clinical and biomarker outcomes expected in the first quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire  on January 21, 2026, and is solely responsible for the information contained","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL5ccDX7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2601678053","title":"Press Release: World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB","url":"https://stock-news.laohu8.com/highlight/detail?id=2601678053","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601678053?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:45","pubTimestamp":1767879900,"startTime":"0","endTime":"0","summary":"Alzheimer's Clinical and Biomarker Outcomes Expected in Q1 2026. CAMBRIDGE, Mass., Jan. 8, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  , a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that Prof. Steven E. Arnold, a world-renowned Alzheimer's disease expert and Professor of Neurology at Harvard Medical School, has joined the Company's Scientific Advisory Board. Prof. Arnold brings decades of experience in neurodegenerative disease research, biomarker-driven clinical development, and translational neuroscience, further strengthening NeuroSense's scientific leadership as it advances PrimeC in ALS and expands its Alzheimer's disease program.\"Prof. Arnold's depth of experience in biomarker-driven clinical development and translational neuroscience aligns closely with how we are advancing our programs,\" said Alon Ben-Noon, Co-Founder and Chief Executive Officer of NeuroSense. \"His perspective will be valua","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","NRSN","BK4132","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurosense-tx.com","stockEarnings":[{"period":"1week","weight":-0.0721},{"period":"1month","weight":-0.2113},{"period":"3month","weight":-0.0263},{"period":"6month","weight":-0.3535},{"period":"1year","weight":-0.2635},{"period":"ytd","weight":0.0256}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.0305},{"period":"6month","weight":-0.0059},{"period":"1year","weight":0.1634},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.157004},{"month":2,"riseRate":0.6,"avgChangeRate":0.184296},{"month":3,"riseRate":0.4,"avgChangeRate":0.037459},{"month":4,"riseRate":0.5,"avgChangeRate":-0.151693},{"month":5,"riseRate":0.25,"avgChangeRate":-0.004252},{"month":6,"riseRate":0.75,"avgChangeRate":0.40415},{"month":7,"riseRate":0,"avgChangeRate":-0.235872},{"month":8,"riseRate":0.5,"avgChangeRate":-0.118473},{"month":9,"riseRate":0.5,"avgChangeRate":0.06987},{"month":10,"riseRate":0,"avgChangeRate":-0.14429},{"month":11,"riseRate":0.75,"avgChangeRate":0.430569},{"month":12,"riseRate":0.25,"avgChangeRate":-0.202897}],"exchange":"NASDAQ","name":"Neurosense Therapeutics Ltd","nameEN":"Neurosense Therapeutics Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Neurosense Therapeutics Ltd(NRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Neurosense Therapeutics Ltd(NRSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Neurosense Therapeutics Ltd,NRSN,Neurosense Therapeutics Ltd股票,Neurosense Therapeutics Ltd股票老虎,Neurosense Therapeutics Ltd股票老虎国际,Neurosense Therapeutics Ltd行情,Neurosense Therapeutics Ltd股票行情,Neurosense Therapeutics Ltd股价,Neurosense Therapeutics Ltd股市,Neurosense Therapeutics Ltd股票价格,Neurosense Therapeutics Ltd股票交易,Neurosense Therapeutics Ltd股票购买,Neurosense Therapeutics Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Neurosense Therapeutics Ltd(NRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Neurosense Therapeutics Ltd(NRSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}